Antibiotics have long been used at sub-therapeutic levels to control incidences of post-weaning diarrhea and to improve growth performance in pigs. However, the current trend world-wide is to eliminate the use of in-feed antibiotics due to increased public concerns over the spread of antibiotic resistance in bacterial pathogens, which poses a threat to public health. Alternatives to in-feed antibiotics are needed. Thymol essential oil exhibits strong in vitro antibacterial activity; however; direct inclusion of essential oils to pig feeds has limited efficacy due to their high volatility, low stability during feed processing, interactions with other feed components and poor availability in lower gut. To solve these problems, we developed lipid matrix beads using thymol and a fatty acid with incorporation of 2% polysaccharides via a melt-granulation technique. Laurie acid was identified as a suitable carrier for thymol. In vitro release of thymol from lipid matrix granules was determined using simulated salivary fluid (SSF), simulated gastric fluid (SGF) and simulated intestinal fluid (SIF), respectively. The lipid matrix granules with 2% polysaccharides exhibited a slow release rate (%) of essential oil and fatty acid in SSF (21.2±2.3; 36±1.1), SGF (73.7±6.9; 54.8±1.7) and SIF (99.1±1.2; 99.1±0.6), respectively. However, the lipid matrix granules without polysaccharides had quick release (%) of essential oil and fatty acid from the SSF (79.9±11.8; 84.9±9.4), SGF (92.5±3.5; 75.8±5.9) and SIF (93.3±9.4; 93.3±4.6), respectively.

Compositions for the immediate release of one or more cannabinoids, in which the compositions comprise a population of particles. Each particle may comprise the one or more cannabinoids and one or more intra-granule excipients. Alternatively, each particle may comprise the one or more cannabinoids and a porous bead core. The composition may be prepared by a method that involves combining the one or more cannabinoids with the one or more intra-granule excipients, and then granulating the combination, such as through fluid bed granulation, shear-induced wet granulation, or spray granulation. The composition may also be prepared by a method that involves mixing the one or more cannabinoids with a population of porous bead cores.

An object of the present invention is to provide a packaging body that can stably store a pharmaceutical composition containing a succinate salt of (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)-4-pentyn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methyl-2-butenamide. According to the present invention, there is provide a packaging body obtained by packaging a succinate salt of (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)-4-pentyn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methyl-2-butenamide, together with zeolite, and a method for stabilizing a pharmaceutical composition.

The present invention relates to a pharmaceutical combination, the pharmaceutical combination comprising a glucokinase activator or a pharmaceutically acceptable salt thereof, an isotopic label thereof, a crystal form thereof, a hydrate, a solvate, a diastereomer or enantiomer, and a K-ATP channel blocker. The present invention further relates to a pharmaceutical composition, a fixed dose compound preparation, and a method for preparing the pharmaceutical composition and the fixed dose compound preparation as well as a use thereof.

An object of the present invention is to provide a granulated product containing a succinate salt of (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)-4-pentyn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methyl-2-butenamide (hereinafter, referred to as Compound A), which has excellent stability. According to the present invention, there is provided a granulated product containing a succinate salt of (S,E)-N-(1-((5-(2-((4-cyanophenyl)amino)-4-(propylamino)pyrimidin-5-yl)-4-pentyn-1-yl)amino)-1-oxopropan-2-yl)-4-(dimethylamino)-N-methyl-2-butenamide and at least one or more additives of the group consisting of magnesium stearate, sodium stearyl fumarate, and hydrogenated oil.

The present application provides methods of treating Pompe disease such as infantile-onset Pompe disease (IOPD) using a pharmaceutical composition comprising an oligosaccharide-acid α-glucosidase (GAA) conjugate, such as avalglucosidase alfa. Also provided are formulations of the oligosaccharide-GAA conjugates.

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

A method of producing a cannabinoid nanoparticle carrier composition for administration to a human and thereafter producing a consumable food product including the cannabinoid nanoparticle emulsification. The cannabinoid nanoparticle carrier composition is combined with a particulate food product, herb or spice, sugar, salt, or particulate preservative, mixed into a slurry or suspension, dried, and then ground to a size suitable for human consumption

Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

The present invention relates to self-emulsifying pharmaceutical compositions in the field of allergen(s) and/or allergenic extract(s). Further within the scope of the invention is self-emulsifying oral pharmaceutical compositions and kits for compounding pharmaceuticals compositions that include at least one allergen as an active agent and one or more pharmaceutically acceptable excipients. The present invention also relates to processes for preparing such compositions. These pharmaceutical compositions are useful in the treatment of various types of allergies such as drug allergy, food allergy, insect allergy, latex allergy, mold allergy, pet allergy, and pollen allergy.